Healthcare provider profile · identity verified

Anita E. Cherian, MD

Internal Medicine · ANTIOCH, CA · NPI 1306924402

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	441	173
Amlodipine Besylate	Amlodipine Besylate	337	123
Levothyroxine Sodium	Levothyroxine Sodium	307	100
Losartan Potassium	Losartan Potassium	239	91
Fluticasone Propionate	Fluticasone Propionate	181	81
Lisinopril	Lisinopril	171	69
Gabapentin	Gabapentin	147	55
Alendronate Sodium	Alendronate Sodium	121	42
Metoprolol Tartrate	Metoprolol Tartrate	119	49
Hydrochlorothiazide	Hydrochlorothiazide	118	44
Albuterol Sulfate Hfa	Albuterol Sulfate	115	77
Famotidine	Famotidine	103	43
Metformin Hcl	Metformin Hcl	99	38
Simvastatin	Simvastatin	85	34
Pantoprazole Sodium	Pantoprazole Sodium	72	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	64	23
Metoprolol Succinate	Metoprolol Succinate	61	24
Alvesco	Ciclesonide	57	26
Furosemide	Furosemide	55	28
Metformin Hcl Er	Metformin Hcl	55	28
Glipizide	Glipizide	54	26
Omeprazole	Omeprazole	54	20
Triamcinolone Acetonide	Triamcinolone Acetonide	51	27
Atenolol	Atenolol	46	16
Tamsulosin Hcl	Tamsulosin Hcl	41	21
Doxycycline Monohydrate	Doxycycline Monohydrate	40	37
Clopidogrel	Clopidogrel Bisulfate	39	16
Trazodone Hcl	Trazodone Hcl	37	suppressed
Cefadroxil	Cefadroxil	36	33
Lovastatin	Lovastatin	36	11
Spiriva Respimat	Tiotropium Bromide	36	18
Fluoxetine Hcl	Fluoxetine Hcl	34	13
Meloxicam	Meloxicam	34	13
Ibuprofen	Ibuprofen	31	14
Pravastatin Sodium	Pravastatin Sodium	31	12
Hydralazine Hcl	Hydralazine Hcl	29	11
Rosuvastatin Calcium	Rosuvastatin Calcium	29	suppressed
Carvedilol	Carvedilol	28	12
Wixela Inhub	Fluticasone Propion/Salmeterol	28	suppressed
Eliquis	Apixaban	27	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	13
Sertraline Hcl	Sertraline Hcl	27	11
Clobetasol Propionate	Clobetasol Propionate	26	11
Nabumetone	Nabumetone	25	21
Naproxen	Naproxen	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Allopurinol	Allopurinol	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Potassium Chloride	Potassium Chloride	20	12
Bupropion Xl	Bupropion Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Humulin N	Insulin Nph Human Isophane	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Jardiance	Empagliflozin	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Sucralfate	Sucralfate	15	suppressed
Ofloxacin	Ofloxacin	14	12
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Prednisone	Prednisone	14	13
Ondansetron Odt	Ondansetron	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Breyna	Budesonide/Formoterol Fumarate	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Mupirocin	Mupirocin	12	12
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error